• Kara Furman, Andrew Giustini, Joshua Branstetter, Gary Woods, and Laura A Downey.
• Stanford Medicine Children's Health, Stanford University, Stanford, California, USA.
• Paediatr Anaesth. 2024 Dec 1; 34 (12): 120012121200-1212.

BackgroundAlthough direct oral anticoagulants (DOACs) have been used in the adult population for over a decade, DOACs use has begun to rise in pediatric populations since FDA approval of rivaroxaban and dabigatran, DOACs offer several advantages for pediatric patients, to other anticoagulants, including a similar safety profile, minimal lab monitoring, and ease of administration. The rise in DOAC use has led to an increasing number of pediatric patients managed on DOACs presenting for elective and urgent procedures. Perioperative management of anticoagulation is often challenging for providers due to the lack of expert consensus guidelines and the difficulty in balancing a patient's thrombotic risk with bleeding risk for a given procedure.AimsUsing the most up to date literature, we provide a focused review on the perioperative management of DOACs in pediatric patients.ConclusionsThis work presents a focused review for pediatric anesthesiologists on clinically available DOACs, perioperative monitoring and management of DOACs, as well as options and indications for reversal. While consensus expert practice guidelines are still needed, we hope this work will familiarize perioperative physicians with these agents, recommended uses, and potential perioperative management.© 2024 John Wiley & Sons Ltd.

20 keywords...

hide…